Yusuke Nakamura to Molecular Targeted Therapy
This is a "connection" page, showing publications Yusuke Nakamura has written about Molecular Targeted Therapy.
Connection Strength
1.327
-
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci. 2016 Apr; 107(4):377-84.
Score: 0.471
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.461
-
Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci. 2018 Mar; 109(3):497-506.
Score: 0.134
-
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
Score: 0.094
-
Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011 Oct 01; 17(19):6272-86.
Score: 0.086
-
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget. 2016 Apr 05; 7(14):17652-64.
Score: 0.030
-
The NSD family of protein methyltransferases in human cancer. Epigenomics. 2015 Aug; 7(5):863-74.
Score: 0.028
-
Identification of a novel oncogene, MMS22L, involved in lung and esophageal carcinogenesis. Int J Oncol. 2012 Oct; 41(4):1285-96.
Score: 0.023